Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \>= 18 years of age~* Patients must be newly diagnosed with primary invasive ductal breast adenocarcinoma.~* Tumor classified as clinically stage T2, T3 or T4 with any N (NX, N1, N2, or N3).~* Tumor does not express the following biomarkers: estrogen receptor, progesterone receptor, Her2/neu~* Adequate organ function defined as:~  * Serum Creatinine \<= 1.5 x upper limit of institutional normal.~ * ALT, AST, ALK Phos \<= 1.5 x upper limit of institutional normal.~ * Bilirubin \<= 1.5 x upper limit of institutional normal.~ * Normal left ventricular function (LVEF \> 50%) by MUGA or ECHO.~Exclusion Criteria:~* No evidence of distant metastasis present by CT, Bone scan, or physical exam. If the bone scan or CT scans demonstrate indeterminate lesions, the nature of these lesions should be further clarified by additional testing such as PET or MRI.~* No prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated with at least greater than 5 years disease free survival.~* Women of child bearing potential may not be currently pregnant or breastfeeding at time of registration and must agree to use adequate contraception.~* Karnofsky Performance Status of \<= 70.~* Patients with known history neural deficiencies (e.g. peripheral neuropathy).~* Patients with a known hearing impairment (hearing loss or severe tinnitus).~* Male patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin + Radiation + Recommended Surgery (Type: EXPERIMENTAL): Cisplatin 75 mg/m\^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection

Based on this trial design, predict the completion outcome and termination type (if applicable).